| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 12th January 2021 | Andre Turenne | 10,443 | Open or private sale | $8.62 | $90,018.66 |
| 12th January 2021 | Allison Dorval | 2,942 | Open or private sale | $8.62 | $25,360.04 |
| 21st May 2020 | Omar Khwaja | 3,500 | Open or private sale | $12.96 | $45,360.00 |
| 3rd April 2020 | Robert W. Hesslein | 3,091 | Open or private sale | $8.51 | $26,304.41 |
| 10th February 2020 | Robert W. Hesslein | 27,500 | Grant/award etc. | $0.00 | |
| 10th February 2020 | Omar Khwaja | 30,000 | Grant/award etc. | $0.00 | |
| 10th February 2020 | Andre Turenne | 81,250 | Grant/award etc. | $0.00 | |
| 10th February 2020 | Allison Dorval | 27,500 | Grant/award etc. | $0.00 | |
| 21st January 2020 | Allison Dorval | 3,128 | Open or private sale | $13.36 | $41,790.08 |
| 21st January 2020 | Andre Turenne | 10,705 | Open or private sale | $13.36 | $143,018.80 |
Voyager Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Ticker: VYGR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1640266
Employees: 185
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $144 M (0%)
Marketable Securities, Current: $85 M (-56%)
Assets, Current: $247 M (-19%)
Property, Plant and Equipment, Net: $20 M (12%)
Assets: $297 M (-16%)
Accounts Payable, Current: $2 M (-49%)
Accrued Liabilities, Current: $18 M (0%)
Liabilities, Current: $68 M (-11%)
Other Liabilities, Noncurrent: $30 M (0%)
Liabilities: $221 M (-13%)
Common Stock, Value, Issued: $37 Th (0%)
Common Stock, Shares, Issued: $37 M (0%)
Retained Earnings (Accumulated Deficit): $346 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $145 Th (39%)
Stockholders' Equity (Parent): $77 M (0%)
Liabilities and Equity: $297 M (-16%)
Revenue: $29 M (-38%)
Research and Development: $29 M (-52%)
General and Administrative Expenses: $8 M (-55%)
Operating Income/Loss: $9 M (-73%)
Other Income, net: $300 Th (-36%)
EPS (basic): $0.23 (-74%)
EPS (diluted): $0.23 (-74%)
News
Voyager Therapeutics: Complicated Story In Gene Therapy Development
18th January 2021
Neurocrine Biosciences Hit By Multiple Setbacks
17th November 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020